These results revealed that PBRM1 inhibition could promote the infiltration of M1 macrophages into RCC, thereby improving the efficacy of anti‐PD‐1 immunotherapy and prolonging the survival of tumor‐bearing mice. The gene discussed is PDCD1; the disease is renal cell adenocarcinoma.